Gufic Biosciences has completed a further investment of USD 50,000 in Selvax Pty Ltd through subscription of 378,350 ordinary shares at AUD 0.20 per share on April 28, 2026. The company informed stock exchanges BSE and NSE about this strategic investment under Regulation 30 of SEBI Listing Regulations on April 29, 2026.

Investment Transaction Details

The investment was executed through cash consideration, marking the company's continued expansion into the biotechnology sector. This transaction follows an earlier intimation dated February 13, 2026, regarding the company's investment plans in Selvax.

About Selvax Pty Ltd

Selvax Pty Limited is an Australian proprietary company incorporated on August 14, 1987, engaged in biopharma research and development. The company specializes in developing novel immunology-based treatments for large solid tumours, with technology fully owned by Selvax. The therapy aims to provide innovative cancer treatments for both animals and humans, with potential applications across various solid tumours including sarcomas, lung cancer, pancreatic, skin, breast, and colorectal cancer.

Financial Performance and Background

Selvax has demonstrated consistent revenue growth over the past three financial years. The total issued share capital of Selvax as of June 30, 2025, stands at AUD 52,85,176.

Strategic Rationale and Regulatory Compliance

The acquisition represents a strategic arrangement for developing immunotherapy solutions in oncology, enabling Gufic Biosciences to diversify into healthcare and biotechnology sectors. The investment provides access to proprietary technology, research capabilities, and potential commercial opportunities in both human and veterinary oncology. The company confirmed that this transaction does not fall within related party transactions, and promoter groups have no interest in Selvax. No governmental or regulatory approvals were required for this acquisition, and the transaction has been completed as reported to the exchanges.

Gufic Biosciences Limited has announced the opening of a special window for shareholders to re-lodge transfer deeds and dematerialize physical shares, following regulatory guidelines issued by the Securities and Exchange Board of India (SEBI).

Special Window Details

The pharmaceutical company has established this facility pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The special window will remain operational from February 05, 2026 to February 04, 2027, providing shareholders with a one-year timeframe to complete their transactions.

Eligibility Criteria

The facility is designed for lodgement of physical securities transfer and dematerialization for shares that were sold or purchased prior to April 01, 2019. This includes cases where transfer requests were previously submitted but were rejected, returned, or not processed due to deficiencies in documents or processes.

Shareholders must meet specific eligibility requirements as outlined in the SEBI circular:

Processing Requirements

Only requests accompanied by original certificates along with transfer deeds and relevant supporting documents will be considered under this special window. The securities transferred through this process will be mandatorily credited to the transferee in dematerialized mode only.

Key restrictions include:

• Securities will remain under lock-in for one year from the date of registration of transfer
• No transfer, lien-marking, or pledging allowed during the lock-in period
• Original security certificates must be available for processing

Contact Information

For queries regarding the re-lodgement process, shareholders can contact the company's Registrar and Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited), located at C-101, Embassy 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. Alternatively, shareholders may reach out to Gufic Biosciences' corporate office at SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400057.

The company has urged all eligible shareholders to take advantage of this special window, which has been introduced specifically for the benefit of investors holding physical shares.